I would like to conduct a survey among cardiac anesthesiologists and perfusionists about the composition of prime solutions. I would greatly appreciate if anyone could answer my questions indicating their suggestions.

For years controversy has raged over the inclusion of colloids in pump primes, with specific emphasis placed on the value of albumin as a routine prime constituent. The adjunct of albumin has the rationale to counteract hypotonicity due to excessive hemodilution that could lead to tissue edema and altered organ function.

Hyponcotic primes could promote tissue edema through interstitial expansion with plasma water. In our institution, as in many centers around the world, albumin has been added for years to CPB prime with the aim to offset these changes, although the benefits associated with this practice is still controversial.

When low-molecular-weight hydroxyethyl starch (HES), came into the market, they have been used as volume-expanding adjuncts to crystalloid primes. As an alternative approach to Albumin. In our institution HES 130/0,4 has been largely used in the last decade for prime solutions.

Recently the safety of HES has been greatly questioned till that the FDA and the European drug agency gave a warning on their use in some categories of critical patients and also in cardiac surgery. As result the italian agency has retired HES solution from the market.

What do you think about this issue. Should we definitely use crystalloid-only primes? Is there a reason to come back to albumin?

More Sergio Bevilacqua's questions See All
Similar questions and discussions